中性粒细胞型哮喘的发病机制及大环内酯类药物的治疗作用

Abstract
Figure/Table
References
Related Citation (15)

[1]	Wenzel S E.Asthma: defining of the persistent adult phenotypes[J]. Lancet,2006,368(9537):804-813.
[2]	Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. updated 2009[EB/OL]. http://ginasthma.org/.
[3]	Chung K F.Clinical management of severe therapy-resistant asthma[J]. Expert Rev Respir Med,2017,11(5):395-402.
[4]	韩国敬, 胡红.重症哮喘表型及内型的研究进展[J].中华老年多器官疾病杂志, 2017,16(3): 169-172.
[5]	Wood L G, Baines K J, Fu J, et al.The neutrophilic inflammatory phenotype is associated with systemic inflammation in asthma[J].Chest, 2012,142(1): 86-93.
[6]	Huang Y J, Nelson C E, Brodie E L, et al.Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma[J].J Allergy Clin Immunol,2011,127(2):372-381.
[7]	Huang Y J, Boushey H A.The microbiome and asthma[J].Ann Am Thorac Soc, 2014,11(Suppl 1):S48-S51.
[8]	Webley W C, Aldridge K L.Infectious asthma triggers: time to revise the hygiene hypothesis[J].Trends Microbiol, 2015,23(7):389-391.
[9]	Taylor S L, Leong L E X, Choo J M, et al.Inflammatory phenotypes in severe asthma are associated with distinct airway microbiology[J].J Allergy Clin Immun,2018,141(1):94-103.
[10]	Webley W C, Hahn D L.Infection-mediated asthma: etiology, mechanisms and treatment options, with focus on Chlamydia pneumoniae and macrolides[J].Respir Res, 2017,18(1):98.
[11]	Teccnio C, Scapini P, Pizzolo G, et al.On the cytokines produced by human neutrophils in tumors[J].Semin Cancer Biol,2013,23(3):159-170.
[12]	李亭亭,柯越海,程洪强.中性粒细胞在哮喘中作用的研究进展[J].浙江大学学报(医学版), 2016,23(9):545-549.
[13]	Schleich F N, Chevremont A, Paulus V, et al.Importance of concomitant local and systemic eosinophilia in uncontrolled asthma[J].Eur Respir J, 2014,44:97-108.
[14]	da Silva J, Hilzendeger C, Moermans C.Raised interferon β, type 3 interferon and interferon stimulated genes-evidence of innate immune activation in neutrophilic asthma[J].Clin Exp Allergy, 2017,47(3):313-323.
[15]	Simpson J L, Carroll M, Yang I A, et al.Reduced Antiviral Interferon Production in Poorly Controlled Asthma Is Associated With Neutrophilic Inflammation and High-Dose Inhaled Corticosteroids[J].Chest,2016,149:704-713.
[16]	Muehling L M, Lawrence M G, Woodfolk J A.Pathogenic CD4+T cells in patients with asthma[J].J Allergy Clin Immunol, 2017,140:1523-1540.
[17]	Newcomb D, Peebles J R.Th17-mediated inflammation in asthma[J].Curr Opinion Immunol, 2013,25:755-760.
[18]	Choi I S.Immune tolerance by induced regulatory T cells in asthma[J].Allergy Asthma Immunol Res, 2012, 4(3):113-115.
[19]	Liu W, Liu S, Verma M, et al.Mechanism of TH2/TH17-predominant and neutrophilic TH2/TH17-low subtypes of asthma[J].J Allergy Clin Immunol, 2017,139:1548-1558.
[20]	Wood L, Baines K, Fu J, et al.The neutrophilic inflammatory phenotype is associated with systemic inflammation in asthma[J].Chest,2012,142:86-93.
[21]	Fu J, Baines K, Wood L, et al. Systemic inflammation is associated with differential gene expression and airway neutrophilia in asthma[J].OMICS, 2013,17:187-199.
[22]	Baines K J, Simpson J L, Wood L G,et al.Systemic upregulation of neutrophil α-defensins and serine proteases in neutrophilic asthma[J]. Thorax, 2011,66:942-947.
[23]	Brusselle G G, VanderStichele C, Jordens P, et al.Azithromycin for prevention of exacerbations in severe asthma(AZISAST):a multicentre randomized double-blind placebo-controlled trial[J].Thorax, 2013, 68: 322-329.
[24]	Kew K M, Undela K, Kotortsi I, ,et al. Macrolides for chronic asthma[J]. Cochrane Db Syst Rev. Macrolides for chronic asthma[J]. Cochrane Db Syst Rev, 2015, 9. No: CD002997.
[25]	Arfe A, Blasi F, Merlino L, et al.Respiratory drugs and macrolides prevent asthma exacerbations: A real-world investigation[J].Respir Med, 2016,119:7-12.
[26]	Altenburg J, de Graaff C S, van der Werf T S, et al. Immuno-modulatory effects of macrolide antibiotics. Part 1: Biological mechanisms[J]. Respiration, 2011, 81:67-74.
[27]	Parnham M J, Haber V E, Giamarellos-Bourboulis E J, et al. Azithromycin: Mechanisms of action and their relevance for clinical applications[J].Pharmacol Therapeu, 2014,143:225-245.
[28]	Tamaoki J, Kadota J, Takizawa H.Clinical implications of the immunomodulatory effects of macrolides[J].Am J Med, 2004,117(Suppl. 9A): S5-11.
[29]	Banjanac M, Munic K V, Nujic K, et al.Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A.1 cells[J].Pharmacol Res, 2012,66:357-362.
[30]	Yamauchi K, Shibata Y, Kimura T, et al.Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon-gamma stimulated macrophages[J].Int J Biol Sci, 2009,5: 667-678.
[31]	Iwamoto S, Azuma E, Kumamoto T, et al.Efficacy of azithromycin in preventing lethal graft-versus-host disease[J].Clin Exp Immunol, 2013, 171: 338-345.
[32]	Lin S J, Yan D C, Lee W I, et al.Effect of azithromycin on natural killer cell function[J].Int Immunopharmacol, 2012,13:8-14.
[33]	Halldorsson S, Gudjonsson T, Gottfredsson M, et al.Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection[J].Am J Respir Cell Mol Biol, 2010, 42: 62-68.
[34]	Liu Y, Pu Y, Li D, et al.Azithromycin ameliorates airway remodeling via inhibiting airway epithelium apoptosis[J].Life Sci, 2017,170:1-8.
[35]	Ding F M, Zhu S L, Shen C, et al.Low-dose clarithromycin therapy modulates CD4+ T cell responses in a mouse model of chronic Pseudomonas aeruginosa lung infection[J].Respirology, 2012,17(4):727-734.
[36]	An T J, Rhee C K, Kim J H,et al.Effects of Macrolide and Corticosteroid in Neutrophilic Asthma Mouse Model[J]. Tuberc Respir Dis (Seoul),2018,81(1):80-87.
[37]	Shinkai M, Henke M O, Rubin B K.Macrolide antibiotics as immunomodulatory medications: Proposed mechanisms of action[J]. Pharmacol Therapeut, 2008,117:393-405.

[1]	. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(8): 645-650.